Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Abbott

Abbott Laboratories' October Price Plunge Is a Signal to Buy

Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.

MarketBeat

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance.

Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Abbott Tightens Annual Sales Forecast As Q3 Sales Miss Expectations

Abbott Laboratories (NYSE:ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.

Benzinga

Abbott Elementary's Season 5 Premiere Had A Lot Of Moving And Shaking, And I Need To Talk About One Specific Change

Well, this will be fun!

Cinemablend

What to Expect From Abbott Laboratories' Next Quarterly Earnings Report

Abbott Laboratories will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 Dividend Kings That Pay - and Beat the Market Too

These Dividend Kings are outperforming the S&P 500 in 2025 while extending decades of payout growth and earning strong buy ratings.

Barchart

Quinta Brunson Said Abbott Elementary's Season 5 Christmas Episode Will Be 'A Game Changer,' And I Have A Few Wild Guesses About Why

Hear me out...

Cinemablend

Why Abbott Elementary Doesn’t Want To Go ‘The Easy Route’ With Janine And Gregory’s Relationship In Season 5

Janine and Gregory fans can celebrate!

Cinemablend

Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb or Sink?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

‘A Goal of Ours’—U.S. Soccer Standouts Talk Growth of Game Ahead of PL Summer Series

Tyler Adams and Tim Howard spoke to Sports Illustrated about the growth of soccer in the U.S.

Sports Illustrated

3 Dividend Stocks With 100+ Years of History and Sky-High Growth

These three century-old companies boast strong buy ratings, 50%+ dividend growth, and rock-solid fundamentals—ideal picks for long-term income investors.

Barchart

Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield

Abbott Laboratories' dividend is safe, the pipeline is strong, and the outlook for growth is positive, making the July price dip a buying opportunity.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q2 Results

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.

Benzinga

Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year.

Benzinga

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.

Benzinga

Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abbott Laboratories (NYSE:ABT) will release earnings results for the second quarter, before the opening bell on Thursday, July 17.

Get all your
news in one place.

100's of premium titles.
One news app.

Cinemablend

Always Sunny In Philadelphia's Gang Was Back At Their Worst In The Abbott Elementary Crossover, But Quinta Brunson Shocked Me With The Biggest Spit Take Moment

Quinta Brunson's Janine vs. Kaitlin Olson's Dee!

BANG Premier

Quinta Brunson: Abbott Elementary cast would 'love to pursue other projects'

Quinta Brunson feels "blessed" that Abbott Elementary is still popular but admitted she's looking forward to a different role in the future.

Barchart

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

Barchart

What to Expect From Abbott Laboratories' Q2 2025 Earnings Report

Abbott is poised to release its second-quarter results next month, and analysts project a single-digit earnings growth.

Barchart

3 Dividend Growth Stocks To Buy and Hold Forever

These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.

Barchart

3 Dividend Aristocrats With Explosive Earnings and Bulletproof Payouts

Discover 3 Dividend Aristocrats with high earnings growth, low payout ratios, and strong analyst ratings: perfect for long-term income investors.

Barchart

Abbott Laboratories Stock: Is ABT Outperforming the Health Care Sector?

Abbott Laboratories has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.